1-9 of 9
Tess Stafford
Close
Sort by
News

FDA Clears AI Diagnostic Tool for Hematologic Conditions

Tess Stafford
Published: 2024
Abstract
Mid-July 2024
View News titled, FDA Clears AI Diagnostic Tool for Hematologic Conditions
News

FDA Approves Four Hematologic Treatments

Tess Stafford
Published: 2024
Abstract
July 2024
View News titled, FDA Approves Four Hematologic Treatments
News

Pulmonary Embolism Response Teams May Change Acute PE Care

Tess Stafford
Published: 2022
Abstract
Mid-November 2022
View News titled, Pulmonary Embolism Response Teams May Change Acute PE Care
News

Patient Race Linked to Relapse Risk and Rituximab Response in iTTP

Tess Stafford
Published: 2022
Abstract
October 2022
View News titled, Patient Race Linked to Relapse Risk and Rituximab Response in iTTP
News

Hematology Post-Roe

Tess Stafford
Published: 2022
Abstract
October 2022 The strong link between hematology and maternal health care makes the recent SCOTUS decision particularly poignant for hematologists and their patients.
View News titled, Hematology Post-Roe
News

HCT and GT Show Similar Outcomes for ADA-SCID in the Contemporary Era

Tess Stafford
Published: 2022
Abstract
September 2022
View News titled, HCT and GT Show Similar Outcomes for ADA-SCID in the Contemporary Era
News

Prophylactic TXA Does Not Prevent Bleeding in Thrombocytopenia From Hematologic Malignancy Treatment

Tess Stafford
Published: 2022
Abstract
September 2022
View News titled, Prophylactic TXA Does Not Prevent Bleeding in Thrombocytopenia From Hematologic Malignancy Treatment
News

AML MRD Testing By NGS Identifies Adults At High Relapse Risk After Allogeneic Transplantation

Tess Stafford
Published: 2022
Abstract
Mid-July 2022
View News titled, AML MRD Testing By NGS Identifies Adults At High Relapse Risk After Allogeneic Transplantation
News

Updated Phase I Results Show Response in R/R MM With Talquetamab, Recommended Phase II Doses

Tess Stafford
Published: 2022
Abstract
Mid-July 2022
View News titled, Updated Phase I Results Show Response in R/R MM With Talquetamab, Recommended Phase II Doses